RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joseph J. Sacco, Kevin Joseph Harrington, Andres Cervantes, Maria de Miguel, Guzman Alonso, Sara Valpione, Anna Olsson-Brown, Tze Y. Chan, Pablo Nenclares, Isla Leslie, Praveen Bommareddy, Alireza Kalbasi, Ben Xie, Dishan Liu, Danielle Ulanet, Vineetha Edavana, Gary Vanasse, Francesca Aroldi, Aglaia Skolariki, Mark R. Middleton
Institutions: University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Institute of Cancer Research, National Institute for Health and Care Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, Universitat de València, INCLIVA Health Research Institute, Hospital Universitario HM Sanchinarro, Vall d'Hebron Institute of Oncology, Cancer Research UK, University of Manchester, The Christie NHS Foundation Trust, University Hospitals Sussex NHS Foundation Trust, Replimune Group, Inc. (United States), University of Oxford, Churchill Hospital
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162550008
Cites:
Cited by:
Related to: